Copyright
©The Author(s) 2021.
World J Gastroenterol. Oct 7, 2021; 27(37): 6231-6247
Published online Oct 7, 2021. doi: 10.3748/wjg.v27.i37.6231
Published online Oct 7, 2021. doi: 10.3748/wjg.v27.i37.6231
Table 4 Therapeutic drug monitoring thresholds used in current practice (Using enzyme-linked immunoassay)
| Drug | Cut-off for serum drug concentration | Cut-off for detectable ADA |
| Infliximab | > 3 μg/mL | Present if > 10 μg/mL |
| Adalimumab | > 5 μg/mL | Present if > 10 μg/mL |
| Certolizumab | > 15 μg/mL | - |
| Ustekinumab | Insufficient evidence to make a suggestion | - |
| Vedolizumab | Insufficient evidence to make a suggestion | - |
- Citation: Albader F, Golovics PA, Gonczi L, Bessissow T, Afif W, Lakatos PL. Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring. World J Gastroenterol 2021; 27(37): 6231-6247
- URL: https://www.wjgnet.com/1007-9327/full/v27/i37/6231.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i37.6231